SCHEMBL5655076

SCHEMBL5655076

Cn1c(=O)n(-c2ccc(F)cc2)c2c3cc(Br)ccc3ncc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 20/20 0.56
MTOR P42345 14/20 0.56
PIK3CD O00329 13/20 0.56
PIK3CG P48736 7/20 0.56
PIK3CB P42338 6/20 0.56
PIK3C2A O00443 2/20 0.47
PIK3C2B O00750 2/20 0.47
PIK3C3 Q8NEB9 2/20 0.47
CHEK1 O14757 1/20 0.47
ABCB11 O95342 1/20 0.47
CSF1R P07333 1/20 0.47
MET P08581 1/20 0.47
PIK3R1 P27986 1/20 0.47
LTK P29376 1/20 0.47
CDK7 P50613 1/20 0.47
NEK2 P51955 1/20 0.47
JAK3 P52333 1/20 0.47
LIMK1 P53667 1/20 0.47
PRKDC P78527 1/20 0.47
ACVR1 Q04771 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31439371 0.86 PIK3CD (0.71) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL31439397 0.86 PIK3CA (0.57) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL31439347 0.85 PIK3CA (0.53) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL31439345 0.85 PIK3CA (0.53) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL31439336 0.84 PIK3CA (0.52) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL14873046 0.84 PIK3CA (0.51) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL27914183 0.84 PIK3CA (0.54) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL31439288 0.84 PIK3CA (0.56) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL31439293 0.84 MTOR (0.49) PIK3CAMTORPIK3CDPIK3CGPIK3CB
SCHEMBL31439395 0.83 PIK3CA (0.51) PIK3CAMTORPIK3CDPIK3CGPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119661531-A Imidazolone compound as well as preparation method and application thereof 北京富龙康泰生物技术有限公司 2025-03-21 CN disclosed
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases CAPRARO HANS-GEORG 2007-09-13 US disclosed
EP-1689747-A1 1H-IMIDAZO [4,5-C] QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2006-08-16 EP disclosed
WO-2005054238-A1 1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213355-A1 1H-Imidazo[4,5-C]Quinoline Derivatives in the Treatment of Protein Kinase Dependent Diseases ABL1, PRKCA, PRKCQ PIK3CA 466/4885MTOR 612/4885PIK3CD 304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.